All In Biotech

Drug Trial Radar · NCT04502693

Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults

A Phase III, Randomized, Controlled, Observer-blind Study to Demonstrate Effectiveness, Immunogenicity and Safety of GSK's Meningococcal Group B and Combined ABCWY Vaccines When Administered to Healthy Adolescents and Young Adults

Last checked: Nov 19, 2026Latest source record: Mar 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,657 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,657

Actual

Start

Aug 14, 2020

Primary completion

Sep 13, 2022

Study completion Sep 13, 2022

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Aug 6, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 10 years, up to 25 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the effectiveness of 2 doses or 3 doses of GSK's licenced meningococcal group B Bexsero (rMenB+OMV NZ) vaccine and of 2 doses of GSK's investigational combined meningococcal (MenABCWY) vaccine (GSK3536819A) in healthy adolescents and young adults. The immunogenicity and safety were evaluated in the study.

Conditions

  • Infections, Meningococcal

Interventions

  • rMenB+OMV NZ vaccineCombination product

    rMenB+OMV NZ vaccine was administered intramuscularly.

  • Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)Biological

    MenACWY vaccine was administered intramuscularly.

  • PlaceboCombination product

    Placebo was administered intramuscularly.

  • MenABCWY-1Combination product

    Lot 1 of the MenABCWY vaccine was administered intramuscularly.

  • MenABCWY-2Combination product

    Lot 2 of the MenABCWY vaccine was administered intramuscularly.

  • MenABCWY-3Combination product

    Lot 3 of the MenABCWY vaccine was administered intramuscularly.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Blood Samples Without Bactericidal Serum Activity Against Each of the Endemic US N. Meningitidis Serogroup B Strains at 1 Month After the 3-dose (0,2,6-M), 2-dose(0,6-M) Vaccination Schedule of rMenB+OMV and 1 Dose of MenACWYTime frame: At 1 month after vaccination schedule (i.e., Day 211 for MenB_0_2_6 group [3-dose schedule] and MenB_0_6 group, and Day 31 for ACWY group)
  2. Percentage of Blood Samples Without Bactericidal Serum Activity Against Each of the Endemic US N. Meningitidis Serogroup B Strains at 1 Month After the 2-dose (0,2-M) Vaccination Schedule of rMenB+OMV and 1 Dose of MenACWYTime frame: At 1 month after vaccination schedule (i.e., Day 91 for the MenB_0_2_6 group [2-dose schedule] and Day 31 for ACWY group)
  3. Percentage of Participants Whose Sera Kill Greater Than or Equal to (>=) 70% of the Strains Tested Using Enc-hSBA at 1 Month After the 3-dose (0,2,6-M) Schedule of rMenB+OMV and 2-dose(0,6-M) Schedule of rMenB+OMVTime frame: At 1 month after vaccination schedule (i.e., Day 211 for MenB_0_2_6 group [3-dose schedule] and MenB_0_6 group)
  4. Percentage of Participants Whose Sera Kill >=70% of the Strains Tested Using Enc-hSBA at 1 Month After the 2-dose (0,2-M) Schedule of rMenB+OMVTime frame: At 1 month after vaccination schedule (i.e., Day 91 for the MenB_0_2_6 group [2-dose schedule])
  5. Geometric Mean Titers (GMTs) Against Serogroups A, C, W and Y for Each Lot (ABCWY-1 Group, ABCWY-2 Group and ABCWY-3 Group) at 1 Month After the Last Vaccination of MenABCWYTime frame: At 1 month after the last vaccination of MenABCWY (Day 211)
  6. Percentage of Participants With 4-fold Rise in hSBA Titers Against N. Meningitidis Serogroups A, C, W and Y at 1 Month After Last MenABCWY Vaccination (Pooled Lots) and MenACWY Vaccination (for the ACWY Group), Relative to BaselineTime frame: At 1 month after vaccination schedule (i.e., Day 211 for the ABCWY_Pooled group and Day 31 for the ACWY Group) compared to Day 1 (baseline)
  7. Percentage of Blood Samples Without Bactericidal Serum Activity Against Each of the Endemic U.S N. Meningitidis Serogroup B Strains at 1 Month After Last MenABCWY Vaccination (Pooled Lots) and MenACWY Vaccination (for the ACWY Group)Time frame: At 1 month after the vaccination schedule (i.e., Day 211 for the ABCWY_Pooled group and Day 31 for the ACWY group)
  8. Percentage of Blood Samples With Bactericidal Serum Activity Against Each of the Endemic U.S N. Meningitidis Serogroup B Strains at 1 Month After the Last MenABCWY Dose (Pooled Lots) and 2-dose(0,2-M) Schedule of rMenB+OMVTime frame: At 1 month after the vaccination schedule (i.e., Day 211 for the ABCWY_Pooled group and Day 91 for the MenB_0_2_6 Group [2-dose schedule])
  9. Percentage of Participants Whose Sera Kill >=70% of the Strains Tested Using Enc-hSBA at 1 Month After the Last Vaccination in the ABCWY Group (Pooled Lots)Time frame: At 1 month after the last vaccination of MenABCWY (Day 211)
  10. Number of Participants With Any Solicited Local Adverse Events (AEs) After the First Study Intervention AdministrationTime frame: During 7 days after the first study intervention administration occurring at Day 1
  11. Number of Participants With Any Solicited Local Adverse Events (AEs) After the Second Study Intervention AdministrationTime frame: During 7 days after the second study intervention administration occurring at Day 61
  12. Number of Participants With Any Solicited Local Adverse Events (AEs) After the Third Study Intervention AdministrationTime frame: During 7 days after the third study intervention administration occurring at Day 181
  13. Number of Participants With Any Solicited Systemic AEs After the First Study Intervention AdministrationTime frame: During 7 days after the first study intervention administration occurring at Day 1
  14. Number of Participants With Any Solicited Systemic AEs After the Second Study Intervention AdministrationTime frame: During 7 days after the second study intervention administration occurring at Day 61
  15. Number of Participants With Any Solicited Systemic AEs After the Third Study Intervention AdministrationTime frame: During 7 days after the third study intervention administration occurring at Day 181
  16. Number of Participants With Any Unsolicited AEs After the First Study Intervention AdministrationTime frame: During the 30 days after the first study intervention administration occurring at Day 1
  17. Number of Participants With Any Unsolicited AEs After the Second Study Intervention AdministrationTime frame: During the 30 days after the second study intervention administration occurring at Day 61
  18. Number of Participants With Any Unsolicited AEs After the Third Study Intervention AdministrationTime frame: During the 30 days after the third study intervention administration occurring at Day 181
  19. Number of Participants With SAEs, AEs Leading to Withdrawal, AESIs and Medically Attended AEsTime frame: Throughout the study period (Day 1 to Day 361)

Locations

112 sites in 7 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Chandler, Arizona

  • GSK Investigational Site

    Glendale, Arizona

  • GSK Investigational Site

    Jonesboro, Arkansas

  • GSK Investigational Site

    Bell Gardens, California

  • GSK Investigational Site

    Canoga Park, California

  • GSK Investigational Site

    Garden Grove, California

  • GSK Investigational Site

    Inglewood, California

  • GSK Investigational Site

    Los Gatos, California

  • GSK Investigational Site

    Cutler Bay, Florida

  • GSK Investigational Site

    Lake City, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    Oviedo, Florida

  • GSK Investigational Site

    West Palm Beach, Florida

  • GSK Investigational Site

    Adairsville, Georgia

  • GSK Investigational Site

    Buford, Georgia

  • GSK Investigational Site

    Columbus, Georgia

  • GSK Investigational Site

    Hinesville, Georgia

  • GSK Investigational Site

    Nampa, Idaho

  • GSK Investigational Site

    Oak Brook, Illinois

  • GSK Investigational Site

    Wichita, Kansas

  • GSK Investigational Site

    Wichita, Kansas

  • GSK Investigational Site

    Bardstown, Kentucky

  • GSK Investigational Site

    Louisville, Kentucky

  • GSK Investigational Site

    Metairie, Louisiana

  • GSK Investigational Site

    Beverly, Massachusetts

  • GSK Investigational Site

    Fall River, Massachusetts

  • GSK Investigational Site

    Grosse Pointe Woods, Michigan

  • GSK Investigational Site

    Minneapolis, Minnesota

  • GSK Investigational Site

    Petal, Mississippi

  • GSK Investigational Site

    Missoula, Montana

  • GSK Investigational Site

    Missoula, Montana

  • GSK Investigational Site

    The Bronx, New York

  • GSK Investigational Site

    Dayton, Ohio

Showing 40 of 112 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.